APA (7th ed.) Citation

Chinot, O. L., & Wick, W. (2016). Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: An exploratory analysis of AVAglio. Neuro-Oncology, 18(9), . https://doi.org/10.1093/neuonc/now046

Chicago Style (17th ed.) Citation

Chinot, Olivier L., and Wolfgang Wick. "Upfront Bevacizumab May Extend Survival for Glioblastoma Patients Who Do Not Receive Second-line Therapy: An Exploratory Analysis of AVAglio." Neuro-Oncology 18, no. 9 (2016). https://doi.org/10.1093/neuonc/now046.

MLA (9th ed.) Citation

Chinot, Olivier L., and Wolfgang Wick. "Upfront Bevacizumab May Extend Survival for Glioblastoma Patients Who Do Not Receive Second-line Therapy: An Exploratory Analysis of AVAglio." Neuro-Oncology, vol. 18, no. 9, 2016, https://doi.org/10.1093/neuonc/now046.